242 related articles for article (PubMed ID: 31928408)
1. Prostate Specific Antigen Criteria to Diagnose Failure of Cancer Control following Focal Therapy of Nonmetastatic Prostate Cancer Using High Intensity Focused Ultrasound.
Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
J Urol; 2020 Apr; 203(4):734-742. PubMed ID: 31928408
[TBL] [Abstract][Full Text] [Related]
2. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
Chen PY; Chiang PH; Liu YY; Chuang YC; Cheng YT
Int J Urol; 2018 Jun; 25(6):615-620. PubMed ID: 29756298
[TBL] [Abstract][Full Text] [Related]
3. Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound.
Mortezavi A; Krauter J; Gu A; Sonderer J; Bruhin J; Reeve KA; Held L; Donati OF; Rupp NJ; Moch H; Sulser T; Eberli D
J Urol; 2019 Oct; 202(4):717-724. PubMed ID: 31042109
[TBL] [Abstract][Full Text] [Related]
4. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
[TBL] [Abstract][Full Text] [Related]
5. An Exploratory Study of Dose Escalation
Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
J Endourol; 2020 Jun; 34(6):641-646. PubMed ID: 32253928
[No Abstract] [Full Text] [Related]
6. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
7. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience.
Mearini L; D'Urso L; Collura D; Zucchi A; Costantini E; Formiconi A; Bini V; Muto G; Porena M
J Urol; 2009 Jan; 181(1):105-11; discussion 111-2. PubMed ID: 19081465
[TBL] [Abstract][Full Text] [Related]
8. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU
Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
[TBL] [Abstract][Full Text] [Related]
10. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
11. High-intensity focused ultrasound for the treatment of prostate cancer: A prospective trial with long-term follow-up.
Mearini L; D'Urso L; Collura D; Nunzi E; Muto G; Porena M
Scand J Urol; 2015; 49(4):267-74. PubMed ID: 25485722
[TBL] [Abstract][Full Text] [Related]
12. Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
Stabile A; Sanchez-Salas R; Tourinho-Barbosa R; Macek P; Pellegrino F; Gandaglia G; Moschini M; Cathala N; Mombet A; Montorsi F; Briganti A; Cathelineau X
J Urol; 2021 Sep; 206(3):638-645. PubMed ID: 33890485
[TBL] [Abstract][Full Text] [Related]
13. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.
Hsu CC; Hsu H; Pickett B; Crehange G; Hsu IC; Dea R; Weinberg V; Gottschalk AR; Kurhanewicz J; Shinohara K; Roach M
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):370-7. PubMed ID: 22672747
[TBL] [Abstract][Full Text] [Related]
15. Prospective Multicenter Phase II Study on Focal Therapy (Hemiablation) of the Prostate with High Intensity Focused Ultrasound.
Ganzer R; Hadaschik B; Pahernik S; Koch D; Baumunk D; Kuru T; Heidenreich A; Stolzenburg JU; Schostak M; Blana A
J Urol; 2018 Apr; 199(4):983-989. PubMed ID: 29107031
[TBL] [Abstract][Full Text] [Related]
16. External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound.
Mattlet A; Limani K; Alexandre P; Hawaux E; Abou Zahr R; Aoun F; Diamand R
Prostate; 2023 Dec; 83(16):1564-1571. PubMed ID: 37574824
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
[TBL] [Abstract][Full Text] [Related]
18. Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
Orczyk C; Barratt D; Brew-Graves C; Peng Hu Y; Freeman A; McCartan N; Potyka I; Ramachandran N; Rodell R; Williams NR; Emberton M; Ahmed HU
J Urol; 2021 Apr; 205(4):1090-1099. PubMed ID: 33315505
[TBL] [Abstract][Full Text] [Related]
19. Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.
Kanthabalan A; Arya M; Freeman A; Mitra AV; Payne H; Peters M; Shah TT; Emberton M; Ahmed HU
J Urol; 2020 Nov; 204(5):950-955. PubMed ID: 32602770
[TBL] [Abstract][Full Text] [Related]
20. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
